- Ticker
- ADIL
- Price
- 0.40
- Stock movement down
- -0.02 (-5.09%)
- Company name
- Adial Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 10.71M
- Ent værdi
- 7.29M
- Pris/omsætning
- -
- Pris/bog
- 1.98
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -81.18%
- 3 års afkast
- -38.32%
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2023-02-06
UDBYTTE
ADIL betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | - |
| Pris til egenkapital | 1.98 |
| EV i forhold til salg | - |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 26.85M |
| EPS (TTM) | -0.61 |
| FCF pr. aktie (TTM) | -0.46 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 0.00 |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsindkomst (TTM) | -16.06M |
| Nettoindkomst (TTM) | -15.70M |
| EPS (TTM) | -0.61 |
| EPS (1 år frem) | -0.56 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenstmargin (TTM) | - |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 5.75M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 6.77M |
| Goodwill | 248.97K |
| Immaterielle aktiver | 4.62K |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 7.74M |
| Kreditor | 278.20K |
| Kortfristet/nuværende langsigtet gæld | 220.25K |
| Summen af kortfristede forpligtelser | 1.33M |
| Sum gæld | 2.33M |
| Aktionærernes egenkapital | 5.41M |
| Materielle nettoaktiver | 4.70M |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -11.81M |
| Investeringsudgifter (TTM) | 0.00 |
| Fri pengestrøm (TTM) | -11.81M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -290.17% |
| Afkast af aktiver | -202.74% |
| Afkast af investeret kapital | -287.25% |
| Kontant afkast af investeret kapital | -216.11% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.42 |
| Daglig høj | 0.42 |
| Daglig lav | 0.39 |
| Daglig volumen | 111K |
| Højeste gennem alle tider | 8.33 |
| 1 års analytiker estimat | 8.50 |
| Beta | 0.59 |
| EPS (TTM) | -0.61 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 1 Mar 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ADIL | S&P500 | |
| Nuværende prisfald fra top notering | -95.21% | -14.21% |
| Højeste prisfald | -97.56% | -56.47% |
| Højeste efterår dato | 12 Dec 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -71.71% | -11.49% |
| Gennemsnitlig tid til nyt højdepunkt | 104 days | 13 days |
| Maks. tid til nyt højdepunkt | 1023 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
10.71M
Markedsværdi kategori
Small-cap
Beskrivelse
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Personale
16
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
William B. Stilley
Land
USA
By
Charlottesville
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Po...
1. februar 2023
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
1. december 2022
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President...
14. november 2022
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enter...
19. oktober 2022
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of t...
26. september 2022
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat) CHARLOTTESVILLE, Va...
26. september 2022
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary Purnovate Inc achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory ...
6. september 2022
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Mod...
6. september 2022
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
1. september 2022
Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises are part of Zacks Screen of the Week article.
29. august 2022
Næste side